Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Colorectal Cancer 1Triple Negative Breast Neoplasms 1Sezary Syndrome 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Myeloid Malignancies 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 301Cyclophosphamide 241Peripheral Blood Stem Cell Transplantation 115fludarabine phosphate 111Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 81Vincristine 79Prednisone 79Mycophenolic Acid 67Doxorubicin 62Whole-Body Irradiation 59Cyclosporine 59Bendamustine Hydrochloride 59Melphalan 57Tacrolimus 54Busulfan 52obinutuzumab 50fludarabine 50Cytarabine 49Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 33ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × magrolimab × Clear all
NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡